Welcome to our dedicated page for Diamedica Therapeutics news (Ticker: DMAC), a resource for investors and traders seeking the latest updates and insights on Diamedica Therapeutics stock.
DiaMedica Therapeutics Inc. develops clinical-stage biopharmaceutical programs for serious ischemic diseases, with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. Its lead candidate, DM199, is a recombinant synthetic form of the KLK1 protein being studied in maternal-fetal and stroke indications.
Company news commonly covers DM199 clinical and regulatory updates, including preeclampsia studies, the ReMEDy2 Phase 2/3 acute ischemic stroke trial, Health Canada clearances and FDA pre-IND interactions. Updates also include financial results, cash runway commentary, equity financing activity, investor conference participation and equity compensation actions under Nasdaq rules.
DiaMedica Therapeutics (Nasdaq: DMAC) will participate in three investor conferences in March 2026, presenting management updates and participating in fireside chats and a company presentation.
Management engagement dates: TD Cowen on March 2 at 11:50 a.m. ET; Barclays on March 10 at 10:00 a.m. ET; Leerink on March 11 at 3:00 p.m. ET. Investors may request 1×1 meetings via conference representatives.
DiaMedica (Nasdaq: DMAC) granted an aggregate of 50,000 stock options on January 15, 2026 as a material inducement to a newly hired non-executive employee whose employment began in December 2025. The options were approved by the Compensation Committee and issued under the Amended and Restated 2021 Employment Inducement Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $8.54 per share (equal to the closing price on January 15, 2026), vest 25% at the one-year anniversary and the remaining 75% in 12 quarterly installments beginning three months after the one-year anniversary, and carry a ten-year term.
DiaMedica Therapeutics (Nasdaq: DMAC) completed an in-person pre-IND meeting with the FDA for a planned study of DM199 in preeclampsia. The FDA requested one additional non-clinical 10-day modified embryo-fetal development and pre-/postnatal development study in rabbits; DiaMedica has begun preparations and expects results by Q2 2026. The company said meeting minutes provide regulatory clarity as it prepares an IND for early-onset preeclampsia.
Separately, an ongoing Phase 2 investigator-sponsored trial in South Africa has dosed >30 women with late-stage PE; interim data reportedly show statistically significant blood pressure reductions, dilation of intrauterine arteries, and no placental transfer of DM199.
DiaMedica Therapeutics (Nasdaq: DMAC) reported third quarter 2025 results and a business update on November 12, 2025. Key clinical updates include completion of cohort 10 and initiation of an up-to-12 participant expansion cohort in the Phase 2 IST for preeclampsia (completion of the expansion expected in 1H 2026), screening to begin soon for a Part 3 fetal growth restriction cohort, and an in-person pre-IND meeting with the FDA for U.S. PE plans. Enrollment in the ReMEDy2 Phase 2/3 AIS trial is nearing 50% of the 200-patient interim-analysis target, expected in 2H 2026. Financials: $55.3M cash and short-term investments as of September 30, 2025, with anticipated runway into 2H 2027. Net loss was $24.0M for the nine months ended September 30, 2025.
DiaMedica Therapeutics (Nasdaq: DMAC) said President and CEO Rick Pauls will participate in the Jefferies Global Healthcare Conference in London on November 17-20, 2025.
Mr. Pauls will deliver a corporate presentation on Thursday, November 20, 2025, 10:00–10:25 AM GMT and will hold one-on-one investor meetings during the conference. DiaMedica is a clinical-stage biopharmaceutical company focused on treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, with lead candidate DM199, a recombinant KLK1 therapeutic.
DiaMedica Therapeutics (Nasdaq: DMAC) will release its third quarter 2025 financial results after market close on Wednesday, November 12, 2025.
The company will host a live conference call and business update on Thursday, November 13, 2025 at 8:00 AM ET (7:00 AM CT) with a simultaneous webcast available at https://app.webinar.net/MlAxZJky3Q7. Listeners are advised to log on or dial in 15 minutes early.
Replay options: telephonic replay available through November 20, 2025 (replay passcode 9449322) and webcast playback accessible on the investor relations events page for 12 months. DiaMedica is a clinical‑stage biopharmaceutical company focused on preeclampsia and acute ischemic stroke; its lead candidate DM199 is a recombinant form of KLK1 used in Asia for vascular indications.
DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, has granted stock options for 490,000 shares to five newly hired non-executive employees under its Amended and Restated 2021 Employment Inducement Incentive Plan.
The options have an exercise price of $6.76 per share, matching the company's closing price on September 18, 2025. The vesting schedule includes 25% after one year and the remaining 75% in quarterly installments over the following three years. The options have a ten-year term and were granted as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, announced its participation in two upcoming investor conferences.
Management will attend the H.C. Wainwright Global Investment Conference from September 8-10, 2025, featuring a corporate presentation on September 9, and the Lake Street Capital Markets Best Ideas Growth Conference on September 11, 2025, for one-on-one meetings.
DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, will participate in the Cantor Global Healthcare Conference in New York City.
CEO Rick Pauls and CBO Dave Wambeke will engage in a fireside chat on September 4, 2025, from 9:10-9:40 am ET at the New York Marriott Marquis. The session will be moderated by Joshua Schimmer, Managing Director at Cantor Fitzgerald. Management will also be available for one-on-one investor meetings during the conference.
DiaMedica Therapeutics (Nasdaq: DMAC) reported significant Q2 2025 developments and financial results. The company announced positive Phase 2 interim data for DM199 in preeclampsia, showing statistically significant reductions in blood pressure and no placental transfer. DiaMedica secured a $30.1 million private placement, extending its cash runway into H2 2027 with a proforma cash balance of $60 million.
Key financial metrics include R&D expenses of $5.8 million for Q2 2025 (up from $3.9M in Q2 2024) and a net loss of $7.7 million (increased from $5.1M). The company's ReMEDy2 Phase 2/3 trial for acute ischemic stroke continues with interim data expected in Q2 2026. Notable corporate developments include inclusion in the Russell 2000® and 3000® Indexes and appointment of Dr. Julie Krop as Chief Medical Officer.